Assessing risks and benefits of genistein and soy

Environmental Health Perspectives

Volumn 114, Issue 6, 2006, Pages

  Setchell, Kenneth D R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZIN; DIETHYLSTILBESTROL; ENDOCRINE DISRUPTOR; ESTROGEN; GENISTEIN; GENISTIN; ISOFLAVONE; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOYBEAN PROTEIN;

ARTIFICIAL MILK; BREEDING; CARDIOVASCULAR RISK; DRUG BLOOD LEVEL; DRUG METABOLISM; EDITORIAL; FOOD INTAKE; HUMAN; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; RISK BENEFIT ANALYSIS; SAFETY; SOYBEAN; SPECIES DIFFERENCE; TOXICITY TESTING;

EID: 33745055720     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.114-a332     Document Type: Editorial

References (21)

1. Brown NM, Setchell KDR. 2001. Animal models impacted by phytoestrogens in commercial chow: implications for pathways influenced by hormones. Lab Investig 81:735-747.
2. Coward L, Barnes NC, Setchell KDR, Barnes S. 1993. Genistein and daidzein, and their glycosides conjugates: anti-tumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem 41:1961-1967.
3. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281:2189-2197.
4. Diel P, Schulz T, Smolnikar K, Strunck E, Vollmer G, Michna H. 2000. Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: estrogenicity profiles and uterotropic activity. J Steroid Biochem Mol Biol 3:1-10.
5. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263.
6. Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, et al. 2004. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 9:116-125.
7. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. 2005. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 21:1441-1452.
8. McLachlan JA, Newbold RR, Bullock BC. 1980. Long-term effects on the female mouse genital tract associated with prenatal exposure to diethylstilbestrol. Cancer Res 40:3988-3999.
9. McLachlan JA, Newbold RR, Burow ME, Li SF. 2001. From malformations to molecular mechanisms in the male: three decades of research on endocrine disrupters. APMIS 109:263-272.
10. Newbold RR. 2004. Lessons learned from perinatal exposure to diethylstilbestrol. Toxicol Appl Pharmacol 199:142-150.
11. NTP-CERHR. 2006a. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Genistein. Research Triangle Park, NC:National Toxicology Program Center for the Evaluation of Risks to Human Reproduction. Available: http://cerhr.niehs.nih.gov/chemicals/ genistein-soy/genistein/Genistein_Report_final.pdf [accessed 17 May 2006].
12. NTP-CERHR. 2006b. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Soy Formula. Research Triangle Park, NC:National Toxicology Program Center for the Evaluation of Risks to Human Reproduction. Available: http://cerhr.niehs.nih.gov/chemicals/ genistein-soy/soyformula/Soy-reportfinal.pdf [accessed 17 May 2006].
13. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O, et al. 1999. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18:4608-4618.
14. Ronas M, Chen Y, Badeaux J, Laurenzana E, Badger T. 2006. Soy protein isolate induces CYP3A1 and CYP3A2 in prepubertal rats. Exp Biol Med 231:60-69.
15. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. 2006. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113:1034-1044.
16. Setchell KDR, Brown NM, Lydeking-Olsen E. 2002. The clinical importance of the metabolite equol: a clue to the effectiveness of soy and its isoflavones. J Nutr 132:3577-3584.
17. Setchell KDR, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, et al. 2005. S-equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 81:1072-1079.
18. Setchell KDR, Zimmer-Nechemias L, Cai J, Heubi JE. 1997. Exposure of infants to phytooestrogens from soy-based infant formula. Lancet 350:23-27.
19. Setchell KDR, Zimmer-Nechemias L, Cai J, Heubi JE. 1998. Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutrition 68:1453S-1461S.
20. Thigpen JE, Setchell KDR, Saunders HE, Haseman JK, Grant MG, Forsythe DB. 2004. Selecting the appropriate rodent diet for endocrine disruptor research and testing studies. ILAR J 45:401-416.
21. Yoshida A, Newbold RR, Dixon D. 1999. Effects of neonatal diethylstilbestrol (DES) exposure on morphology and growth patterns of endometrial epithelial cells in CD-1 mice. Toxicol Pathol 27:325-333.